Kelly Oluoch

Kelly Oluoch

Auto-generated profile, based on publicly available information

Kelly Oluoch

Kenya Medical Training College (KMTC), Nairobi, Kenya

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2022 in JMIR Pediatrics and Parenting
Verified
Journal Article
Open access
JOHN KYALO MUTHUKAJOHN KYALO MUTHUKA
JOHN KYALO MUTHUKA
MKMichael Kiptoo
Michael Kiptoo
KOKelly Oluoch
Kelly Oluoch
JNJapheth Mativo Nzioki
Japheth Mativo Nzioki
ENEverlyn Musangi Nyamai
Everlyn Musangi Nyamai
Background: COVID-19 was first identified in Wuhan, China, in December 2019, spreading to the rest of the globe, becoming a pandemic. Some studies have shown an association between pregnancy status and severe COVID-19 with a cytokine storm, whereas others have shown contrasting results. Objective: The aim of this study was to examine the relationship between pregnancy status and the clinical COVID-19 severity characterized by the cytokine storm through a systematic review and meta-analysis. Methods: We searched the Google Scholar, PubMed, Scopus, Web of Science, and Embase databases to identify clinical studies suitable for inclusion in this meta-analysis. Studies reporting pregnancy status and comparing the COVID-19 severity cytokine storm outcome were included. COVID-19 severity characterized by a cytokine storm was described using parameters such as intensive care unit admission, invasive mechanical ventilation, mechanical ventilation, hospital admission, pro- and anti-inflammatory cytokine levels, consolidation on chest computed tomography scan, pulmonary infiltration, extreme fevers as characteristic of a cytokine storm, syndromic severity, higher neutrophil count indicative of a cytokine storm, and severe COVID-19 presentation. Results: A total of 17 articles including data for 840,332 women with COVID-19 were included. This meta-analysis revealed a correlation between positive pregnancy status and severe COVID-19 with a cytokine storm (random-effects model odds ratio [OR] 2.47, 95% CI 1.63-3.73; P<.001), with a cumulative incidence of 6432 (14.1%) and 24,352 (3.1%) among pregnant and nonpregnant women with COVID-19, respectively. The fixed-effects model also showed a correlation between pregnancy status and severe COVID-19 with a cytokine storm (OR 7.41, 95% CI 7.02-7.83; P<.001). Considerable heterogeneity was found among all pooled studies (I²=98%, P<.001). Furthermore, the updated analysis showed substantially low heterogeneity (I²=29 %, P=.19), and the funnel plot revealed no publication bias. The subanalysis between single-center and multicenter studies demonstrated similar heterogeneity (I2=72% and 98%, respectively). Sensitivity analysis on each subgroup revealed that pregnancy was significantly related to severe COVID-19 with a cytokine storm from single-center studies (fixed-effects model OR 3.97, 95% CI 2.26-6.95; P<.001) with very low heterogeneity (I²=2%, P=.42). Conclusions: Being pregnant is clearly associated with experiencing a severe course of COVID-19 characterized by a cytokine storm. The COVID-19 pandemic should serve as an impetus for further research on pregnant women diagnosed with COVID-19 to map out the salient risk factors associated with its severity. Trial Registration: PROSPERO CRD42021242011; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=242011.

5 July 2024 in COVID
Verified
Journal Article
Open access
PDF file
JOHN KYALO MUTHUKAJOHN KYALO MUTHUKA
JOHN KYALO MUTHUKA
JNJapeth Mativo Nzioki
Japeth Mativo Nzioki
JKJack Oluoch Kelly
Jack Oluoch Kelly
EMEverlyn Nyamai Musangi
Everlyn Nyamai Musangi
LCLucy Chepkemei Chebungei
Lucy Chepkemei Chebungei
MKMichael Kibet Kiptoo
Michael Kibet Kiptoo
Objectives: We aimed to assess the prevalence of long COVID-19 and estimate the average time to its diagnosis and meta-regression for covariates. Methods: We conducted a systematic review, meta-analysis, and meta-regression from 43 studies (367,236 patients) (June 2020–August 2022). With the random-effects model, the pooled prevalence of long COVID-19 was measured. Publication bias was ascertained, and meta-regression analysis was performed on predetermined covariates. The trial was registered with PROSPERO (CRD42022328509). Results: The pooled prevalence of long COVID-19 was 42.5% (95% CI 36% to 49.3%), with 25% and 66% at four and two months, respectively. Mostly, long COVID-19 signs and symptoms occurred at three (54.3%) to six (57%) months (p < 0.0001), further increasing at 12 months (57.9%, p = 0.0148). Hypertension was significantly associated with long COVID-19 at 32% (0.322 (95% CI 0.166, 0.532) (p < 0.001) and hospital re-admission contributed to 17% (Q = 8.70, df = 1, p = 0.0032) (R2 = 0.17). All the covariates explained at least some of the variance in effect size on long COVID-19 at 53% (Q = 38.81, df = 19, p = 0.0047) (R2 analog = 0.53). Conclusion: The prevalence of long COVID-19 was 42.5% when linked with a cardiovascular disorder. Hospital re-admission majorly predicted the incidence of long COVID-19. Clinical and methodological characteristics in a specific study contributed to over 50% of long COVID-19 events, with most signs and symptoms occurring between 3 and 6 months and increasing at 12 months.

6 October 2025 in JMIRx Med
Verified
Journal Article
Open access
JOHN KYALO MUTHUKAJOHN KYALO MUTHUKA
JOHN KYALO MUTHUKA
DMDianna Kageni Mbari-Fondo
Dianna Kageni Mbari-Fondo
FWFrancis Muchiri Wambura
Francis Muchiri Wambura
KOKelly Oluoch
Kelly Oluoch
JNJapheth Mativo Nzioki
Japheth Mativo Nzioki
RNRosemary Nabaweesi
Rosemary Nabaweesi
Background: The COVID-19 pandemic presented many unknowns for pregnant women, with anemia potentially worsening pregnancy outcomes due to multiple factors. Objective: This review aimed to determine the pooled effect of maternal anemia interventions and associated factors during the pandemic. Methods: Eligible studies were observational and included reproductive-age women receiving anemia-related interventions during the COVID-19 pandemic. Exclusion criteria comprised non-English publications, reviews, editorials, case reports, studies with insufficient data, sample sizes below 50, and those lacking DOIs. A systematic search of PubMed, Scopus, Embase, Web of Science, and Google Scholar identified articles published between December 2019 and August 2022. Risk of bias was evaluated using the Cochrane Risk of Bias 2 tool for randomized trials and the National Institutes of Health’s assessment tool for observational studies. Pooled rate ratios (RRs) with 95% CIs were calculated in Review Manager 5.4.1. Synthesis included subgroup analysis, meta-regression, and publication bias checks to assess intervention effectiveness. Results: This meta-analysis included 11 studies with 6129 pregnant women. Of these, 3591 (59%) were in the intervention group and 2538 (41%) were in the comparator group. Effects were recorded for 1921 (53.4%) women in the intervention group and 1350 (53.1%) in the comparator group. The cumulative impact ranged from 23% to 81%, averaging 56%. The initial analysis showed no significant effect on anemia prevention (RR 0.79, 95% CI 0.61‐1.02; P =.07), with high heterogeneity ( I ²=97%). Sensitivity analysis excluding 4 outlier studies improved the effect size to a significant level at 39% (RR 0.61, 95% CI 0.43‐0.87; P =.006). Subgroup analysis revealed substantial heterogeneity ( I ²=87.2%). Intravenous sucrose had a poor impact (RR 1.31, 95% CI 1.17‐1.47; P <.001), while medicinal or herbal interventions showed benefit (RR 0.81, 95% CI 0.73‐0.90; P =.006). Educational interventions yielded a 28% effect (RR 0.72), medicinal administration 19% (RR 0.81), iron supplementation 17% (RR 0.83), and intravenous ferric carboxylmaltose 15% (RR 0.85; P <.02). Additional sensitivity analysis confirmed a pooled positive effect of 17% (RR 0.83, 95% CI 0.79‐0.88; P <.001), with minimal heterogeneity ( I ²=0%). Regionally, effectiveness was highest in Africa (RR 0.84, 95% CI 0.79‐0.89; P <.001). Multicenter studies and those with 2020 data were predictive of better outcomes (RR 0.84 and RR 0.50, respectively). Despite initial heterogeneity and publication bias, interventions showed utility in mitigating maternal anemia in targeted subgroups and regions. Conclusions: Maternal anemia interventions during the COVID-19 pandemic showed modest, context-specific effectiveness, with declining impact from 2020 to 2022. Although high heterogeneity and study inconsistencies limited generalizability, significant benefits were observed particularly in African and multicenter studies. The pandemic exposed gaps in maternal health systems, emphasizing the need for tailored interventions, stronger data infrastructure, and resilient care strategies in future global crises.

23 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
JOHN KYALO MUTHUKAJOHN KYALO MUTHUKA
JOHN KYALO MUTHUKA
ENEverlyn Nyamai
Everlyn Nyamai
COChristopher Onyango
Christopher Onyango
KOKelly Oluoch
Kelly Oluoch
RNRosemary Nabaweesi
Rosemary Nabaweesi
Aims: The aims of this meta-analysis were to assess: the prevalence of Post-Acute COVID-19 sequalae in HIV positive patients; average time of diagnosis; and meta-regress for possible moderators of PACS.Methods: A standard search strategy was used in PubMed, and then later modified according to each specific database to get the best relevant results. These included Medline indexed journals; PubMed Central; NCBI Bookshelf and publishers' Web sites in line with the Preferred Reporting Items for Systematic Review and Meta-Analysis statement. Search terms included “long COVID-19 or post-acute COVID-19 syndrome/sequalae”, “persons living with HIV or HIV. The criteria for inclusion were published clinical articles reporting HIV in association with long COVID-19, further, the average time to an event of post-acute COVID-19 sequelae among primary infected patients with COVID-19. Random-effects model was used. Rank Correlation and Egger's tests were used to ascertain publication bias. Sub-group, sensitivity and meta-regression analysis were conducted. A 95% confidence intervals were presented and a p-value < 0.05 was considered statistically significant. Review Manager 5.4 and comprehensive meta-analysis version 4 (CMA V4) were used for the analysis. The review/trial was PROSPERO registered (CRD42022328509).Results: A total of 43 studies reported post-acute COVID-19 syndrome. Of those, five reported post-acute COVID-19 sequalae in PLHIV. Prevalence of post-acute COVID-19 sequalae was 43.1% (95% CI 20.5% to 68.9%) in persons living with HIV (PLWH). The average time to PACS diagnosis was 4 months at 64% [0.64 (95% CI 0.230, 0.913) (P < 0.0000), I2= 93%] and at one year to PACS diagnosis was at 70 %, however with non-significant correlation (P > 0.05). On comorbidities, asthenia was associated with PACS at 17.6 % [0.176 (95% CI 0.067, 0.385) (P = 0.008), I2= 86%] while fatigue at 82%, however not related with PACS event incidence (P < 0.05). Americas, Asian and European regions showed PACS events rates of 82%, 43% and 19 % respectively (P<0.05) relative to HIV infection. Conclusion: PACS prevalence in PLWH was 43% occurring at an average time of 4 months at 64% and 70 % at 12 months however non-significant with PACS. Asthenia was significantly associated with PACS at 17.6 % while fatigue at 82%, however not related with PACS event incidence. Americas recorded the highest PACS event rates in PLWH.

27 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JOHN KYALO MUTHUKAJOHN KYALO MUTHUKA
JOHN KYALO MUTHUKA
LWLispah Wanjiku
Lispah Wanjiku
COChrisphine Onyango
Chrisphine Onyango
KOKelly Oluoch
Kelly Oluoch
MKMary T. Kioko
Mary T. Kioko
SKSara Kim
Sara Kim
Background: Autism spectrum disorder (ASD) is a lifelong neurodevelopmental condition for which timely diagnosis is critical to early intervention, family support, and equitable access to care. However, substantial disparities in access to ASD diagnostic services persist across socioeconomic, geographic, clinical, and health-system contexts. This systematic review and meta-analysis synthesized evidence on determinants of access across the ASD diagnostic pathway, from recognition and referral to diagnostic completion and timely diagnosis. Methods: We systematically searched MEDLINE/PubMed, Embase, Scopus, Web of Science, Global Health, and grey-literature sources for studies published between January 2004 and December 2024. Eligible studies examined determinants of ASD diagnostic completion, diagnostic pathways, diagnostic timeliness, or barriers and facilitators to diagnostic access. Two reviewers independently extracted data and assessed methodological quality using the Mixed Methods Appraisal Tool (MMAT). Quantitatively comparable estimates were synthesized using random-effects models with restricted maximum likelihood estimation. Heterogeneity was assessed using Cochran’s Q, I2, tau2, and 95% prediction intervals. Pre-specified subgroup analyses, meta-regression, sensitivity analyses, funnel-plot assessments, and Bayesian random-effects analyses were undertaken. Results: The search identified 4,899 records; after removal of 537 records without associated data, 4,362 records underwent title/abstract screening. 3,800 records were excluded, 562 reports were sought for retrieval, and 450 full-text reports were assessed after 112 could not be retrieved. Ultimately, 22 unique studies met the inclusion criteria. Nine unique studies contributed 23 quantitative effect estimates, while the remaining studies contributed to the narrative synthesis. The evidence covered socioeconomic, geographic, family, communication, screening, child developmental, provider, and health-system determinants. The overall random-effects meta-analysis yielded a pooled diagnostic access outcome of 74.1% (95% CI 65.8-81.1%), with substantial heterogeneity (Qe=209.95, p<0.001; I2=88.4%, 95% CI 79.1-94.4%; tau2=0.691) and a wide 95% prediction interval of 32.8-94.4%. Bayesian analysis produced a highly concordant pooled estimate of 73.3% (95% CrI 65.3-80.2%), with I2=87.5% and tau=0.833, and satisfactory MCMC convergence (R-hat=1.000). By outcome domain, pooled successful outcomes were highest for diagnostic pathways (89.3%, 95% CI 70.1-96.7%), followed by timely diagnosis (76.3%, 95% CI 62.9-86.0%), and lowest for diagnostic completion (67.1%, 95% CI 61.8-72.0%) (Qm=5.98, p=0.050). Timely diagnosis demonstrated particularly high heterogeneity (I2=91.2%), whereas diagnostic completion showed moderate heterogeneity (I2=40.6%). Across determinant domains, frequentist pooled estimates were 79.5% for child developmental/neurobehavioral factors, 74.2% for family/socioeconomic/perceptual factors, 68.0% for intervention/care-navigation factors, and 63.6% for provider/clinical recognition factors. Bayesian estimates were 76.7% (BF=53.76), 72.9% (BF=226.32), 64.3% (BF=25.60), and 53.7% (BF=0.684), respectively. Meta-regression indicated that determinant category (Qm=13.48, p=0.004) and effect measure (Qm=7.81, p=0.020) significantly explained between-study variation, whereas age group (p=0.203) and geographic region (p=0.453) did not. Family/socioeconomic factors had significantly larger effect sizes (B=2.703, 95% CI 0.661-4.744; p=0.009), as did child developmental/neurobehavioral factors (B=1.516, 95% CI 0.047-2.985; p=0.043). Potential small-study effects were detected by two of three asymmetry tests, although the Rosenthal fail-safe N was 1,723. Trim-and-fill identified seven potentially missing estimates, with an adjusted pooled effect of 68.4% (95% CI 27.7-109.1%). Importantly, exclusion of two influential outlying estimates produced a pooled outcome of 77.1% (95% CI 71.6-81.9%), indicating that the principal finding was robust. Conclusions: Approximately three-quarters of observed ASD diagnostic outcomes represented successful access, but the substantial heterogeneity indicates that diagnostic access is highly context-dependent. Families were more likely to successfully navigate diagnostic pathways than to complete diagnostic assessment, while timely diagnosis showed the greatest variability across settings. Family and socioeconomic circumstances and child developmental characteristics emerged as particularly important determinants, whereas provider-related effects were more heterogeneous and uncertain. Improving equitable ASD diagnosis requires interventions spanning the entire diagnostic pathway, including developmental surveillance, screening, referral coordination, family navigation, provider capacity, specialist availability, and mechanisms to ensure completion of diagnostic assessment. Greater longitudinal and implementation research is particularly needed in low- and middle-income countries, where diagnostic infrastructure and specialist capacity remain limited.

29 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JOHN KYALO MUTHUKAJOHN KYALO MUTHUKA
JOHN KYALO MUTHUKA
RZRuvimbo Zimunya
Ruvimbo Zimunya
ASAndrina Simengwa
Andrina Simengwa
COChrisphine Onyango
Chrisphine Onyango
KOKelly Oluoch
Kelly Oluoch
DNDesire A. Nshimirimana
Desire A. Nshimirimana
This systematic review and meta-analysis aimed to estimate the overall effectiveness of ASD interventions and identify sources of heterogeneity using frequentist and Bayesian approaches. A systematic search of PubMed/MEDLINE, Embase, Web of Science, and Scopus was conducted for studies published between January 1, 2004, and April 30, 2025. Mainly, randomized controlled trial studies with extractable intervention outcomes were included. A total of 41 studies (n=3,008) were synthesized using random-effects models (REML), Bayesian hierarchical modeling, meta-regression, and sensitivity analyses following PRISMA guidelines. The pooled random-effects estimate showed a significant positive effect of ASD interventions (effect size = 0.506, 95% CI: 0.392–0.619; z = 8.72, p < .001), corresponding to an estimated success proportion of 62% (95% CI: 59%–65%). Heterogeneity was substantial (Q□(40) = 238.78, p < .001; I² = 82.45%; τ² = 0.069, 95% CI: 0.028–0.137; τ = 0.262), with H² = 5.70 and a wide prediction interval (−0.020 to 1.031), indicating strong between-study variability. Bayesian meta-analysis confirmed a comparable effect (posterior mean = 0.619, 95% CrI: 0.592–0.646), with τ = 0.273 and I² ≈ 82.5%, and MCMC diagnostics showed stable convergence (R-hat ≈ 1.00). Publication bias analyses indicated significant funnel plot asymmetry (Egger-type regression: z = 3.429, p < .001; weighted regression: t = 9.573, p < .001), while rank correlation was non-significant (τ = −0.178, p = .103). Trim-and-fill analysis imputed 10 studies, reducing the pooled effect to 0.374 (95% CI: 0.258–0.491; τ = 0.338), though the effect remained significant (p < .001). Sensitivity analyses excluding influential studies yielded a stable effect (0.505, 95% CI: 0.401–0.609), with persistent heterogeneity (I² = 75.49%; Q□(38) = 190.21, p < .001; τ² = 0.043). Subgroup analyses showed highest effects for digital/technology-based interventions (0.672; 67%; I² = 0%), followed by nutritional (0.635; 64%; I² = 73.81%), behavioral (0.630; 63%; I² = 74.78%), and pharmacological (0.627; 63%; I² = 0%) interventions, while physical/occupational therapies showed lower effects (0.523; 52%; I² = 63.35%) and combined interventions showed borderline effects (0.593; 59%; I² = 19.96%); subgroup differences were significant (Q□5) = 22.63, p < .001). Regional effects were similar and non-significant (Q□(2) = 0.73, p = .694): North America (0.619; I² = 84.21%), Europe (0.626; I² = 62.34%), and Asia (0.659; I² = 0%). Age at intervention onset did not significantly moderate effects (Q□(5) = 0.98, p = .964), although variability was observed across children, adolescents, adults, and toddlers. Meta-regression identified significant moderators including intervention context (Q□= 18.159, p = .020), outcome domain (Q□= 19.588, p = .003), age at start (Q□= 17.795, p = .003), and intervention category (Q□= 31.714, p < .001), while follow-up duration and intervention duration were not significant. Bayesian subgroup analyses confirmed robustness, with strongest evidence for pharmacological (BF → ∞), behavioral (BF ≈ 832.50), and digital interventions (BF ≈ 30.92). In conclusion, ASD interventions demonstrate a moderate and statistically significant overall effect (∼0.50–0.62), with substantial heterogeneity driven primarily by intervention type, context, and participant characteristics, and findings were consistent across frequentist, Bayesian, and sensitivity analyses, supporting robust but context-dependent effectiveness.